<< Read Full Article
<< Read Full Article
Slowly, step by step, Vytorin is expanding its market share and raising the hopes of investors in Merck(MRK Quote) and Schering-Plough(SGP Quote), which have created this cholesterol pill from two separate drugs.
Vytorin's progress has come primarily at the expense of AstraZeneca's (AZN Quote) Crestor, which was approved for the U.S. market in August 2003.
"Vytorin continues to grow while Crestor is pulling back," says Albert L. Rauch of A.G. Edwards. "But Vytorin isn't impacting Zetia or Zocor." Schering-Plough's Zetia and Merck's Zocor are sold separately as cholesterol treatments; they also are the two ingredients in Vytorin. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet